



NLS Pharma Announces Poster Presentation On Efficacy and Safety Data of a Controlled Release (CR) Formulation of Mazindol in Adults with ADHD at AACAP's & APSARD's Annual Meeting in the US

Stans/Switzerland, October 31, 2017 - NLS Pharma (NLS), a Swiss biotech group focusing on the development of novel treatments for ADHD and other cognitive disorders and impairments, announced today that an abstract revealing new data for the company's lead compound, NLS-1 (mazindol CR), has been selected for a poster presentation at the 2017 American Academy of Child & Adolescent Psychiatry (AACAP) Annual Meeting and at 2018 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.

The poster is titled 'A Phase II Study to Determine the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with Attention-Deficit/Hyperactivity Disorder'.

"Data showed mazindol CR - previously scheduled as a C4 drug - has a robust effect on symptoms of ADHD with a placebo-adjusted effect size of 1.09. This effect size is similar or higher to what has been seen with traditional C2 stimulants in the treatment for ADHD in other studies. In addition NLS-1 was well tolerated and its safety-profile seems to be closer to non-stimulants" concluded Nelson Handal, M.D., Chief Medical Officer of NLS.

"The promising phase II results are very encouraging and indicative of the potential for mazindol C.R. to make a difference in the lives of millions of patients suffering from ADHD across the globe," said Alex Zwyer, CEO of NLS.

About NLS Pharma

NLS Pharma is a privately owned, Swiss-based biotech group focusing on the development of first-in-class treatments for ADHD, sleep disorders, cognitive impairment and other neurological disorders that remain largely underdiagnosed and for which unmet medical needs are significant. NLS Pharma has built a large portfolio of promising clinical-stage medicines being developed by an experienced team of proven experts in ADHD and sleep-related disorders and working closely with key opinion leaders.

NLS Pharma Contacts

Alex Zwyer, CEO, az@nls-pharma.com

Hervé Girsault, Head of M&A and Business Development, hg@nls-pharma.com